OA11231A - Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer - Google Patents

Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer Download PDF

Info

Publication number
OA11231A
OA11231A OA9900276A OA9900276A OA11231A OA 11231 A OA11231 A OA 11231A OA 9900276 A OA9900276 A OA 9900276A OA 9900276 A OA9900276 A OA 9900276A OA 11231 A OA11231 A OA 11231A
Authority
OA
OAPI
Prior art keywords
alkyl
phenyl
halo
amino
hydroxy
Prior art date
Application number
OA9900276A
Other languages
English (en)
Inventor
Shama Mohammed Kajiiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11231A publication Critical patent/OA11231A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9900276A 1997-06-16 1999-12-10 Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer OA11231A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
OA11231A true OA11231A (en) 2003-05-26

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900276A OA11231A (en) 1997-06-16 1999-12-10 Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (fr)
JP (1) JP3713051B2 (fr)
KR (1) KR100392573B1 (fr)
CN (1) CN1259868A (fr)
AP (1) AP9801261A0 (fr)
AR (1) AR013090A1 (fr)
AT (1) ATE235905T1 (fr)
BG (1) BG103946A (fr)
BR (1) BR9810616A (fr)
CA (1) CA2294399C (fr)
CO (1) CO4950607A1 (fr)
DE (1) DE69812933T2 (fr)
DK (1) DK0986387T3 (fr)
DZ (1) DZ2518A1 (fr)
EA (1) EA199901043A1 (fr)
ES (1) ES2196559T3 (fr)
GT (1) GT199800081A (fr)
HN (1) HN1998000091A (fr)
HR (1) HRP980328B1 (fr)
HU (1) HUP0004624A3 (fr)
ID (1) ID23014A (fr)
IL (1) IL132765A0 (fr)
IS (1) IS5259A (fr)
MA (1) MA24569A1 (fr)
NO (1) NO996206L (fr)
NZ (1) NZ500662A (fr)
OA (1) OA11231A (fr)
PA (1) PA8453601A1 (fr)
PE (1) PE82899A1 (fr)
PL (1) PL337651A1 (fr)
PT (1) PT986387E (fr)
SK (1) SK169699A3 (fr)
TN (1) TNSN98088A1 (fr)
TR (1) TR199903074T2 (fr)
UA (1) UA57081C2 (fr)
WO (1) WO1998057633A1 (fr)
ZA (1) ZA985182B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139502A0 (en) 1998-05-12 2001-11-25 Warner Lambert Co Combination of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
WO2000016778A1 (fr) * 1998-09-24 2000-03-30 Merck & Co., Inc. Procede de traitement du cancer
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2632091C (fr) 2000-12-19 2011-03-22 Pfizer Products Inc. Formes cristallines de sels de 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinoleine-2-one, 2,3-dihydroxybutanedioate et procede de preparation
AU2002249812B2 (en) 2000-12-21 2005-11-10 Nicox S.A. Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635114T2 (de) * 1995-08-09 2006-03-02 Banyu Pharmaceutical Co., Ltd. Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids

Also Published As

Publication number Publication date
AR013090A1 (es) 2000-12-13
PE82899A1 (es) 1999-08-26
ZA985182B (en) 1999-12-17
DZ2518A1 (fr) 2003-02-01
DK0986387T3 (da) 2003-07-14
UA57081C2 (uk) 2003-06-16
PA8453601A1 (es) 2000-05-24
HUP0004624A3 (en) 2002-11-28
AU724676B2 (en) 2000-09-28
AU7445998A (en) 1999-01-04
CA2294399C (fr) 2004-03-16
SK169699A3 (en) 2000-06-12
WO1998057633A1 (fr) 1998-12-23
GT199800081A (es) 1999-12-07
KR100392573B1 (ko) 2003-07-23
JP3713051B2 (ja) 2005-11-02
ID23014A (id) 1999-12-30
DE69812933D1 (de) 2003-05-08
TR199903074T2 (xx) 2000-05-22
PL337651A1 (en) 2000-08-28
IL132765A0 (en) 2001-03-19
HRP980328A2 (en) 1999-04-30
HUP0004624A2 (hu) 2001-10-28
IS5259A (is) 1999-11-19
JP2000513031A (ja) 2000-10-03
ES2196559T3 (es) 2003-12-16
HRP980328B1 (en) 2002-06-30
EP0986387A1 (fr) 2000-03-22
CO4950607A1 (es) 2000-09-01
NO996206L (no) 2000-02-15
AP9801261A0 (en) 1999-12-11
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
CA2294399A1 (fr) 1998-12-23
NO996206D0 (no) 1999-12-15
MA24569A1 (fr) 1998-12-31
ATE235905T1 (de) 2003-04-15
NZ500662A (en) 2001-10-26
DE69812933T2 (de) 2003-11-06
EP0986387B1 (fr) 2003-04-02
BR9810616A (pt) 2000-09-12
HN1998000091A (es) 1999-09-29
KR20010013839A (ko) 2001-02-26
BG103946A (bg) 2000-07-31
PT986387E (pt) 2003-06-30
TNSN98088A1 (fr) 2005-03-15

Similar Documents

Publication Publication Date Title
US7307071B2 (en) RAF-MEK-ERK pathway inhibitors to treat cancer
US20050014783A1 (en) Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
OA11231A (en) Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer
KR101354237B1 (ko) 골수종 치료를 위한 ｈｄａｃ 저해제의 용도
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
TWI786723B (zh) 噠嗪并吲哚衍生物及其用途
US11129830B2 (en) PAC-1 combination therapy
EP2182941B1 (fr) Inhibiteurs multikinase à utiliser dans le traitement du cancer
JP2007063288A (ja) エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
US20060178348A1 (en) Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
Tamanoi et al. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions
Chin et al. Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB
AU724676C (en) Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US20030114503A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
US20190151289A1 (en) Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) Histone Demethylase
WO2005105078A1 (fr) Derives d'indole utiles pour traiter une resistance a des agents anti-tumoraux
MXPA99011798A (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
US20020151563A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
CZ448699A3 (cs) Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
EP3503888A1 (fr) Inhibiteurs du mutants bcr-abl et leur utilisation
WO2021086912A1 (fr) Inhibition combinée de pikfyve et de kinase map p38 pour le traitement du cancer
US5179113A (en) Treatment of central nervous disorders with imidazole compounds
WO2002002116A2 (fr) Traitement therapeutique du cancer au moyen d'un inhibiteur de la proteine kinase c
CA2120234A1 (fr) Agents chimiotherapeutiques de type 2-aminopropanediol-1,3
Halabi A Synthetic Lethal Screen for NF-kB-Dependent Plasma Cell Disorders